GasGene

Executive Summary

GasGene is a Chinese biotechnology company pioneering novel gas-based therapeutics for cardiovascular and respiratory diseases. Founded in 2017 and headquartered in Beijing, the company leverages the therapeutic potential of medical gases such as hydrogen and nitric oxide, delivered via proprietary formulations or devices. Focused on non-invasive treatment options for chronic conditions, GasGene is at the Phase 1 stage of development. With a team of 50-200 employees, the company operates in a niche but rapidly evolving field of gas medicine. While still in early clinical stages, GasGene's approach could offer significant advantages over traditional therapies, including reduced side effects and improved patient compliance. However, the company faces typical biotech risks such as regulatory hurdles, clinical trial outcomes, and competitive landscape dynamics.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Data Readout60% success
• Q4 2026Strategic Partnership or Licensing Deal50% success
• H1 2027Series B or Subsequent Funding Round70% success